home / stock / bicx / bicx news

BICX News and Press, BioCorRx Inc. From 02/27/24

Stock Information
Company Name: BioCorRx Inc.
Stock Symbol: BICX
Market: OTC
Website: biocorrx.com
Menu
BICX BICX Quote BICX Short BICX News BICX Articles BICX Message Board
Get BICX Alerts

News, Short Squeeze, Breakout and More Instantly...
BICX - Expected US Company Earnings on Tuesday, February 27th, 2024

First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
BICX - Expected US Company Earnings on Tuesday, February 20th, 2024

Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...

BICX - Expected US Company Earnings on Tuesday, February 13th, 2024

ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...

BICX - BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors

ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceutic...
BICX - BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President

ANAHEIM, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, announced the appointment of Louis Lucido as Interim Pr...

BICX - BioCorRx Reports Business Update for the Third Quarter of 2023

ANAHEIM, CA - ( NewMediaWire ) - November 14, 2023 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended September 30, 2023, a...

BICX - BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder

Company Hopes in 30 Days to Begin Making Its Drug Candidate Available to Help Patients and Address Public Health Crisis ANAHEIM, CA - ( NewMediaWire ) - August 15, 2023 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) today announced its submission to the US Food and Drug Admi...
BICX - BioCorRx Reports Business Update for the Second Quarter of 2023

On Track to Meet 2023 Regulatory Milestones ANAHEIM, CA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today...

BICX - BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder

ANAHEIM, CA - ( NewMediaWire ) - July 18, 2023 -  BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced the submission of a fast track application to the U.S. Food and...

BICX - BioCorRx GAAP EPS of -$0.13

2023-05-16 09:01:03 ET BioCorRx press release ( OTCQB:BICX ): Q1 GAAP EPS of -$0.13. For further details see: BioCorRx GAAP EPS of -$0.13
Previous 10 Next 10